The US Food and Drug Administration (FDA) approved TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The IOL will be available to patients later this year.
The TECNIS PureSee IOL is the first and only FDA‑approved EDOF IOL with no warning of loss of contrast sensitivity.
According to Johnson & Johnson, the IOL’s manufacturer, 97% of patients reported no very bothersome visual disturbances with the TECNIS PureSee IOL, and 97% said they would recommend this IOL to friends or family. The IOL reduced patient reliance on glasses after surgery, as well.
The TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia.
Source: Press Release
Related Content
